User:Mr. Ibrahem/Tucatinib

Mr. Ibrahem/Tucatinib
Clinical data
Pronunciation	too-KA-tih-nib
Trade names	Tukysa
Other names	ONT-380, ARRY-380
AHFS/Drugs.com	Monograph
MedlinePlus	a620032
License data	EU EMA: by INN; US DailyMed: Tucatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2)
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Chemical and physical data
Formula	C26H24N8O2
Molar mass	480.532 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5;
	InChI InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31); Key:SDEAXTCZPQIFQM-UHFFFAOYSA-N;

Tucatinib, sold under the brand name Tukysa, a medication used to treat HER2-positive breast cancer.^[4] Specifically it is used in cases which are localized but advanced or which have spread to other parts of the body.^[4] It is used together with capecitabine and trastuzumab when other treatments have not worked.^[4] It is taken by mouth.^[4]

Common side effects include diarrhea, nausea, tiredness, inflammation of the mouth, liver problems, and rash.^[4] A rash that may occur is known as palmar-plantar erythrodysesthesia.^[2] Use during pregnancy may harm the baby.^[1] It is a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2).^[2]^[1]

Tucatinib was approved for medical use in the United States and Australia in 2020,^[2]^[1] and in Europe in 2021.^[4] In the United States it costs about 21,000 USD per month as of 2021.^[5]

References[edit]

^ ^a ^b ^c ^d ^e "Tukysa". Therapeutic Goods Administration (TGA). 21 August 2020. Archived from the original on 1 October 2020. Retrieved 22 September 2020.
^ ^a ^b ^c ^d "Tucatinib Monograph for Professionals". Drugs.com. Retrieved 20 September 2021.
^ "Tukysa- tucatinib tablet". DailyMed. Archived from the original on 28 January 2021. Retrieved 21 January 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Tukysa EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 22 March 2021. Retrieved 18 February 2021.
^ "Tukysa Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 20 September 2021.

[TGA2021-1] "Tukysa". Therapeutic Goods Administration (TGA). 21 August 2020. Archived from the original on 1 October 2020. Retrieved 22 September 2020.

[AHFS2021-2] "Tucatinib Monograph for Professionals". Drugs.com. Retrieved 20 September 2021.

[Tukysa_FDA_label-3] "Tukysa- tucatinib tablet". DailyMed. Archived from the original on 28 January 2021. Retrieved 21 January 2021.

[EPAR2021-4] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Tukysa EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 22 March 2021. Retrieved 18 February 2021.

[5] "Tukysa Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 20 September 2021.

[1]

[2]

[3]

[4]

[5]